|
|
|||||||||||||||||||||||
Article Navigation
|
Lycopene Effective with Prostate Cancer Treatmentby: Darin Ingels Men with prostate cancer who take supplemental lycopene in addition to surgical removal of the testicles may experience less active disease, less bone pain, and live longer than those who only have surgical removal of the testicles, according to a new study in British Journal of Urology International (2003;92:375–8). This is exciting news for millions of men who have to undergo aggressive treatment for advanced prostate cancer. Prostate cancer is the most common cancer found in men over the age of 50 years, with more than 200,000 new cases each year in the United States. The cause of prostate cancer, like many other cancers, is unknown; however, some studies suggest alterations in testosterone metabolism may play a role in its development. Prostate cancer is generally slow growing and may not cause any symptoms until late in the disease. Symptoms may include frequent or painful urination, dribbling after urination, sensation of incomplete emptying of the bladder, or blood in the urine. The symptoms of prostate cancer are similar to those of a non-cancerous condition called benign prostatic hyperplasia (BPH), so men experiencing these symptoms should consult their physician for an accurate diagnosis. In the new study, 54 men with advanced prostate cancer were randomly assigned to have surgical removal of the testicles (orchidectomy) alone or orchidectomy plus oral supplementation with 4 mg of lycopene a day. Measurements of PSA (a blood marker of prostate cancer activity), bone scans, and urinary flow were taken initially and every three months for two years. Men receiving lycopene started on the day of their surgery. After six months, PSA had significantly decreased in both groups, indicating a reduction in prostate cancer activity. However, PSA levels in those receiving lycopene were more than 65% lower than in those who did not receive lycopene. After two years, PSA levels in the lycopene treatment group had fallen into the normal range, while those who only underwent surgery still had PSA levels more than twice the upper limit of normal. Urinary symptoms significantly improved in both groups, but better improvement was again observed in the lycopene group. The lycopene group also experienced less bone pain. The survival rates after two years in the lycopene-plus-surgery group and surgery-only groups were 87% and 78%, respectively, a statistically significant difference. No adverse side effects were observed in men taking lycopene.LycopeneLycopene is one of a group of compounds called carotenoids. It is found in high amounts in tomatoes. The findings of this study corroborate the findings of other similar studies examining the effectiveness of lycopene in the treatment of prostate cancer. However, the amount used in the current study (4 mg per day) was substantially less than the amounts used in other studies (30 mg per day). It may also help stimulate the immune system and has been shown to cause cancer cells to die on their own. Although more research is needed to clarify what amount of lycopene is most effective, men with prostate cancer may benefit from taking daily lycopene supplements. Eating one moderately sized tomato a day also provides approximately 4 mg of lycopene. Other tomato products, such as an 8-ounce portion of tomato juice or tomato paste may provide up to 25 mg of lycopene. Latest Cancer News:Hormone drugs for prostate cancer may hurt heart (Reuters via Yahoo! News) Prostate cancer treatments that cut off the supply of male hormone raise cholesterol, worsen blood sugar and make men fatter and thus likely raise the risk of heart attack, too, doctors said on Monday. Auriemma to donate ties on eBay for cancer fund (AP via Yahoo! Sports) Geno Auriemma plans to auction off the neck ties he wears during the rest of UConn's games this season. The school says money raised by the auctions will benefit the Kay Yow/WBCA Cancer Fund. The North Carolina State University women's basketball coach died a year ago after a long fight with breast cancer. Approval Expanded for Breast Cancer Drug Tykerb (HealthDay via Yahoo! News) MONDAY, Feb. 1 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for Tyberb (lapatinib) to include postmenopausal women with hormone- and HER2-positive advanced breast cancer who require hormone therapy. Cancer, Autism Push By Obama to Spur New Medicines (Update2) (Bloomberg) Feb. 1 (Bloomberg) -- President Barack Obama proposed increasing the National Institutes of Health budget by $1 billion, or 3.2 percent, in fiscal 2011, earmarking $6 billion for cancer research and $222 million for work in autism. Heart Risk From Prostate Cancer Hormone Therapy (WebMD) Androgen-blocking hormone therapy for prostate cancer may raise the risk of heart disease, warns an expert panel representing heart, cancer, and urology organizations. Cancer, Autism Push in Obama Budget Plan to Spur 30 New Drugs (Bloomberg) Feb. 1 (Bloomberg) -- President Barack Obama increased the National Institutes of Health budget proposal by $1 billion, or 3.2 percent, in fiscal 2011, earmarking $6 billion for cancer research and $222 million for work in autism. Targeting Cancer Stem Cells May Eradicate Tumors (MedicineNet.com) Title: Targeting Cancer Stem Cells May Eradicate Tumors Category: Health News Created: 1/29/2010 4:10:00 PM Last Editorial Review: 2/1/2010 Three-Fourths of Cancer Patients Have Severe Flares of Pain (MedicineNet.com) Title: Three-Fourths of Cancer Patients Have Severe Flares of Pain Category: Health News Created: 1/29/2010 12:10:00 PM Last Editorial Review: 2/1/2010 Scammer Allegedly Lies About Cancer (ABC News) Prosecutor says Md. woman lied about terminal cancer to steal money. Cancer - Health - Conditions and Diseases - Organizations - United States Childhood cancer project under way (Chicago Sun-Times) What's touted as the biggest effort ever to find all of the genetic mutations that cause childhood cancer is now under way. The privately funded project will complement the Cancer Genome Atlas,an eight-year National Institutes of Health initiative focusing largelyon adult malignancies, says NIH director Dr. Francis Collins. Pfizer says Sutent breast cancer trials fail - Reuters
|
||||||||||||||||||||||
Copyright © 2006 CancerAdvice.org